Motley Fool Premium
  1. Stocks
    2. /
  2. Bausch Health Companies Inc. (TSX: BHC)
    3. /

TSX:BHC (Bausch Health Companies Inc.)

About BHC

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Bausch Health Companies Inc. (TSX: BHC) Latest News

    Dividend Stocks

    Will Negative-Beta Stocks Help Outperform the TSX?

    | David Jagielski

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has seen returns of over 4% year to date, while the TSX has seen losses.

    Read more »

    The Motley Fool
    Investing

    Could Valeant Pharmaceutical Intl Inc. Hit $30?

    | Joey Frenette

    Valeant Pharmaceutical Intl Inc. (TSX:VRX)(NYSE:VRX) appears to be turning a corner. Could a huge rally be on the horizon?

    Read more »

    The Motley Fool
    Top TSX Stocks

    Top Stocks for August

    | Motley Fool Staff

    Top stocks for August include Fairfax Financial Holdings Ltd. (TSX:FFH) and Baytex Energy Corp (TSX:BTE)(NYSE:BTE).

    Read more »

    The Motley Fool
    Dividend Stocks

    These 2 Stocks Are Ridiculously Cheap

    | Jason Phillips

    Bargain-hunters take note: Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) went “from the outhouse to the penthouse, and back to the outhouse…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Is it Comeback Time?

    | Demetris Afxentiou

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to make deals and pay down debt. Is it time to reconsider investing?

    Read more »

    Investing

    Valeant Pharmaceuticals Intl Inc. Will Do Almost Anything to Lower Debt

    | Will Ashworth

    The latest asset sale by Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shows it’s fanatical about debt reduction, regardless of the possible…

    Read more »

    The Motley Fool
    Investing

    This Stock Has Nearly Doubled Since April: How Much Higher Can it Climb?

    | Chris MacDonald

    Why my price target of $25 for Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) still stands and, in fact, appears more likely…

    Read more »

    The Motley Fool
    Investing

    Why Is Valeant Pharmaceuticals Intl Inc. up 30% Since June 1?

    | Jacob Donnelly

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has multiple debt-repayment strategies, but with shares up so much already, wait for a pullback.

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. With Papa Is a Great Buy

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been a tough stock to own up until a few months ago. Here's why…

    Read more »

    Investing

    This 1 Company May Still Be the Best Contrarian Play of the Year

    | Chris MacDonald

    Here's why Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may still be one of the best contrarian plays for 2017.

    Read more »

    The Motley Fool
    Investing

    Can Joe Papa Make Valeant Pharmaceuticals Intl Inc. a High Flyer Again?

    | Joey Frenette

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is starting to look like a great contrarian play. Should you load up today?

    Read more »

    The Motley Fool
    Investing

    What’s the Next Stop for Valeant Pharmaceuticals Intl Inc.?

    | Ryan Goldsman

    With a little tailwind, investors still need to be cautious of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

    Read more »